TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06619587: A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tum

Sponsor: Genentech, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 410 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$6,974,352

Rescue Site Savings

+$4,618,152

Unlock Full NCT06619587 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06619587 Rescue Dossier →